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Targeted production of reactive oxygen species in
mitochondria to overcome cancer drug resistance
Hai Wang1,2,3, Zan Gao 4, Xuanyou Liu5, Pranay Agarwal1,3, Shuting Zhao1,3, Daniel W. Conroy6, Guang Ji 7,
Jianhua Yu2,8, Christopher P. Jaroniec 6, Zhenguo Liu3,5, Xiongbin Lu9, Xiaodong Li4
& Xiaoming He 1,2,3,10
Multidrug resistance is a major challenge to cancer chemotherapy. The multidrug resistance
phenotype is associated with the overexpression of the adenosine triphosphate (ATP)-driven
transmembrane efﬂux pumps in cancer cells. Here, we report a lipid membrane-coated silica-
carbon (LSC) hybrid nanoparticle that targets mitochondria through pyruvate, to speciﬁcally
produce reactive oxygen species (ROS) in mitochondria under near-infrared (NIR) laser
irradiation. The ROS can oxidize the NADH into NAD+ to reduce the amount of ATP available
for the efﬂux pumps. The treatment with LSC nanoparticles and NIR laser irradiation also
reduces the expression and increases the intracellular distribution of the efﬂux pumps.
Consequently, multidrug-resistant cancer cells lose their multidrug resistance capability for at
least 5 days, creating a therapeutic window for chemotherapy. Our in vivo data show that the
drug-laden LSC nanoparticles in combination with NIR laser treatment can effectively inhibit
the growth of multidrug-resistant tumors with no evident systemic toxicity.
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Multidrug resistance of cancer cells is a major reason forthe failure of chemotherapy1,2. Chemotherapy can killthe drug-sensitive cancer cells, but the drug-resistant
cells left behind can cause tumor recurrence (or relapse) and even
cancer metastasis3,4. As a result of the failure to eliminate tumor
relapse in many cancer patients with chemotherapy, multidrug-
resistant cancer cells have attracted a great deal of attention in the
ﬁeld of oncology for several decades. An important advance in the
understanding of cancer drug resistance is the identiﬁcation of
P-glycoprotein (P-gp) and other related transporters-based efﬂux
pumps in the plasma membrane of some cancer cells. These efﬂux
pumps could recognize and catalyze the efﬂux of various antic-
ancer drugs from cancer cells5,6. Rational approaches to target the
mechanisms of cancer drug resistance are emerging as a novel
strategy to improve the clinical outcome of chemotherapy.
Nanoparticles have been explored to overcome the efﬂux pump-
mediated drug resistance by delivering a high concentration of
intracellular drugs7,8. However, existing nanoparticles are incap-
able of inhibiting the function of the efﬂux pump directly.
The most extensively characterized efﬂux pumps, including
ABCB1 (known as MDR1 or P-glycoprotein), ABCC1 (known as
MRP1), and ABCG2 (known as BCRP or MXR), belong to the
adenosine triphosphate (ATP)-binding cassette (ABC) transpor-
ter superfamily9,10. Therefore, inhibiting the function of ABC
transporters should be an effective strategy to overcome cancer
drug resistance. As ATP is indispensable for the efﬂux pumps/
transporters to function, cancer drug resistance may be overcome
by inhibiting the production of ATP in cancer cells11. ATP is
synthesized by ATP synthase powered by a concentration gra-
dient of protons in mitochondria12. The proton gradient is gen-
erated by an electron transport chain with electrons donated
mainly from nicotinamide adenine dinucleotide with hydrogen
(NADH)13. The nature of the electron transport chain is rooted
in several oxidation–reduction reactions14. Therefore, one possi-
ble way to inhibit the production of ATP is to consume NADH
by oxidizing it into NAD+.
As illustrated in Fig. 1a, here we report a lipid membrane-
coated silica-carbon (LSC) hybrid nanoparticle for targeted
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Fig. 1 A schematic illustration of the strategy for overcoming cancer drug resistance. a The transmembrane P-glycoprotein (P-gp) efﬂux pump driven by
adenosine triphosphate (ATP) is a major mechanism of cancer multidrug resistance. In this study, a novel lipid membrane-coated silica-carbon (LSC)
nanoparticle is designed to target the monocarboxylate transporters (MCTs) on mitochondria through the pyruvate groups on the surface of the LSC
nanoparticle. With near infrared (NIR, 800 nm) laser irradiation, the LSC nanoparticles produce reactive oxygen species (ROS) to oxidize NADH into
NAD+ in mitochondria, which compromises ATP production. This results in dysfunction of the P-gp efﬂux pumps. In addition, the treatment of LSC
nanoparticles with NIR laser irradiation (LSC + L) leads to not only transmembrane but also intracellular distribution of the P-gp efﬂux pumps, although the
total amount of the efﬂux pumps is only slightly (albeit signiﬁcantly) reduced. Collectively, the LSC + L treatment can be used to overcome the multidrug
resistance of cancer cells, which is demonstrated using three different chemotherapy drugs in this study: doxorubicin hydrochloride (DOX), paclitaxel
(PTX), and irinotecan (CPT-11). b Owing to their nanoscale size (~45 nm), the DOX-laden LSC (LSC-D) nanoparticles can preferentially accumulate in
tumor as a result of the enhanced permeability and retention (EPR) effect of tumor but not normal vasculature to minimize systemic toxicity of the
chemotherapy drug. After arriving in tumor, the LSC-D nanoparticles can be taken up by multidrug-resistant cancer cells, but the DOX released out of the
nanoparticles can still be pumped out of the cells for the LSC-D treatment alone. Importantly, with NIR laser irradiation, the drug resistance of the
multidrug-resistant cancer cells can be overcome and effective tumor destruction ensues. In contrast, free DOX can diffuse into both normal tissue (which
causes systemic toxicity) and the multidrug-resistant tumor. Moreover, free DOX can be pumped out of the multidrug-resistant cancer cells and further
diffuse back into blood perfusion, leading to ineffective cancer therapy. All mouse and mitochondrion images were created using ChemBioDraw Ultra 12.0
and their color was further adjusted in Powerpoint
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Fig. 2 Synthesis and characterization of nanoparticles. a A schematic illustration of the procedure for preparing colloidal carbon sphere (CCS) nanoparticles
using glucose, producing silica-carbon (SC) nanoparticles using the CCS and tetraethyl orthosilicate (TEOS), modifying the SC nanoparticles with (3-
Aminopropyl) trimethoxysilane (APTMS) to form SC-A nanoparticles, and coating the SC-A nanoparticles with phospholipid
dipalmitoylphosphatidylcholine (DPPC) to produce LSC nanoparticles. The pyruvate group can be formed during the hydrothermal process. b, c Scanning
(SEM, b) and transmission (TEM, c) electron microscopy images of the CCS and SC nanoparticles synthesized with different reaction times showing that
SC nanoparticles of ~35 nm with a homogeneous size distribution can be obtained after 6 h of reaction. Since the SC nanoparticles do not have core–shell
structure, the silica should not cover the whole surface of the nanoparticles. Therefore, the lipid membrane should not completely cover the surface of the
LSC nanoparticles because the lipid only interacts with silica through APTMS. Scale bar: 500 nm in b and 100 nm in c. d TEM image of lipid membrane-
coated SC (LSC) nanoparticles showing the lipid membrane on the surface of the nanoparticles (indicated by arrows). Scale bar: 50 nm. e The production
of singlet oxygen by the LSC nanoparticles under NIR irradiation as compared with LSC nanoparticles without NIR laser irradiation (w/o laser, 1 mgml−1). f
The NIR irradiation (1.0W cm−2) time and LSC nanoparticle concentration (0.06–0.5 mgml−1) dependent increase of temperature. g UV-Vis absorbance
of LSC nanoparticles and DOX-laden LSC (LSC-D) nanoparticles showing successful encapsulation of DOX in the LSC nanoparticles with an absorbance
peak at ~480 nm
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production of reactive oxygen species (ROS) in the mitochondria
of tumor cells under near infrared (NIR, 800 nm) laser irradia-
tion, which can oxidize NADH to minimize the production of
ATP and overcome multidrug resistance. The combined treat-
ment of the LSC nanoparticles and NIR laser irradiation can also
decrease
the amount of the transmembrane P-gp efﬂux pumps by reducing
the overall expression of the pump and increasing its intracellular
distribution, to sensitize multidrug-resistant cancer cells to che-
motherapy. Moreover, the size of the LSC nanoparticles is
appropriate for utilizing the enhanced permeability and retention
(EPR) effect of the tumor vasculature for in vivo tumor targeting
to reduce the systemic toxicity of chemotherapy (Fig. 1b). Fur-
thermore, unlike free drug that may be pumped out of the
multidrug-resistant cancer cells to further diffuse out of tumor
and back into blood perfusion, the drug released out of the LSC
nanoparticles can stay in cancer cells and tumor because the
function of drug efﬂux pumps is compromised for at least ﬁve
days after NIR laser irradiation in the presence of the
nanoparticles.
Results
Preparation and characterization of nanoparticles. First, col-
loidal carbon sphere (CCS) nanoparticles were synthesized
through a hydrothermal synthesis approach by using glucose
(Fig. 2a)15. According to previous studies16–18, pyruvaldehyde
groups can be formed during the hydrothermal process (Fig. 2a).
The structure of pyruvaldehyde is largely similar to pyruvate,
which can speciﬁcally bind with the monocarboxylate transpor-
ters (MCTs) on the outer surface of mitochondria19,20. The
function of MCTs is to actively transport pyruvate into mito-
chondria21. Therefore, we hypothesize that the pyruvate-
decorated nanoparticles can speciﬁcally target mitochondria.
Here, we used a speciﬁc pyruvate detection assay to determine its
existence in CCS nanoparticles. As shown in Supplementary
Fig. 1, 50 µg of CCS nanoparticles contain ~0.15 µg of pyruvate
groups. However, the CCS nanoparticles are difﬁcult to disperse
in water and tend to form large aggregates (Supplementary Fig. 2a
and b). According to dynamic light scattering (DLS, Supple-
mentary Fig. 2b) and scanning (SEM, Fig. 2b and Supplementary
Fig. 3) and transmission (TEM, Fig. 2c) electron microscopy
analyses, the CCS nanoparticles are ~200–300 nm in diameter.
This size is too large to utilize the EPR effect of tumor vasculature
to passively target tumors in vivo22–24. In order to overcome this
problem, the CCS nanoparticles were exposed to tetraethyl
orthosilicate (TEOS, Fig. 2a) for varying lengths of time (3, 6, and
12 h). After 3 h of exposure, the size of the hybrid silica-CCS (SC)
nanoparticles was reduced (Fig. 2b), but aggregates were still
observed in SEM and TEM images (Fig. 2b, c and Supplementary
Fig. 3). SC nanoparticles of ~35 nm in diameters that could be
stably dispersed in water were obtained after 6 h of TEOS expo-
sure (Fig. 2b, c, Supplementary Figs. 2a–c and 3). However, the
size of the resultant SC nanoparticles increased slightly as the
exposure time was extended to 12 h (Fig. 2b, c and Supplementary
Figs. 2d and 3). Therefore, SC nanoparticles obtained after 6 h of
exposure to TEOS were used for all subsequent experiments. The
formation of SC nanoparticles with a greatly reduced size may be
owing to the chemical reaction between TEOS and CCS. This is
conﬁrmed by using proton nuclear magnetic resonance (1H
NMR) and Fourier transform infrared (FTIR) spectroscopy
(Supplementary Figs. 4–5 and Supplementary Note 1).
In order to improve the biocompatibility of the SC nanopar-
ticles, we further modiﬁed their surface with APTMS for
absorbing dipalmitoylphosphatidylcholine (DPPC), to form lipid
membrane-coated SC (LSC) nanoparticles25. The lipid membrane
is visible in the TEM images of the resultant LSC nanoparticles
(Fig. 2d). The LSC nanoparticles are ~45 nm in diameter, and can
be homogeneously dispersed in water with excellent stability
(Supplementary Fig. 6). Although the total amount (~0.058 µg) of
pyruvate groups in 50 µg of LSC nanoparticles is reduced
compared with CCS nanoparticles (Supplementary Fig. 1), it
should not decrease the density of the pyruvate group on the LSC
nanoparticles (Supplementary Note 2). Moreover, the LSC
nanoparticles exhibit strong optical absorption in the NIR region
and the absorbance at 800 nm shows a linear correlation with the
nanoparticle concentration in water (Supplementary Fig. 7).
To determine the potential application of the LSC nanopar-
ticles to produce ROS inside cells, we further identiﬁed the types
of free radicals that can be produced by the nanoparticles under
NIR laser irradiation (1W cm−2, LSC + L). A singlet oxygen (1O2)
sensor was applied to speciﬁcally detect the 1O2 free radical. As
shown in Fig. 2e and Supplementary Fig. 8, the LSC nanoparticles
exhibit an excellent photodynamic capability as demonstrated by
the time- and concentration-dependent production of 1O2 in
deionized water. Furthermore, 5-(diethoxyphosphoryl)−5-
methyl-1-pyrroline-N-oxide (DEPMPO, a spin trap for hydroxyl
radicals (·OH)26) and terephthalic acid (TA) assays were used to
conﬁrm the production of ·OH by LSC + L with the electron
paramagnetic resonance (EPR) and ﬂuorescence spectroscopy,
respectively (Supplementary Fig. 9 and Supplementary Note 3).
In addition, the LSC nanoparticles have excellent photothermal
effect with NIR laser irradiation (1W cm−2, Fig. 2f), and this
photothermal effect is stable under multiple cycles (Supplemen-
tary Fig. 10).
Moreover, the LSC nanoparticles can be used for drug
encapsulation and delivery owing to the silica. We encapsulated
doxorubicin hydrochloride (DOX) into the LSC nanoparticles to
form LSC-D nanoparticles, with an encapsulation efﬁciency of
82.7± 1.5 at a feeding ratio of 1:20 (DOX:nanoparticles). The
UV-Vis absorbance spectrum of LSC-D nanoparticles has a peak
at ~480 nm for DOX, which is absent from the spectrum of LSC
nanoparticles, indicating successful encapsulation of DOX
(Fig. 2g). The LSC-D nanoparticles are also stable in water
(Supplementary Fig. 6b). The in vitro release of DOX from LSC-
D nanoparticles is negligible (<4%) after 30 h of incubation at
37 °C (Supplementary Fig. 11a). Interestingly, the drug release
can be triggered and precisely controlled with the dose of by NIR
laser irradiation (Supplementary Fig. 11), which should be
ascribed to laser induced heating25.
Intracellular distribution of LSC-D nanoparticles. NCI/RES-
ADR multidrug-resistant cancer cells were used in this study27,
and their resistance to free DOX was conﬁrmed by incubating
with different concentrations of free DOX. Indeed, no red
ﬂuorescence of DOX is observable in the 2D-cultured NCI/RES-
ADR cells after 6 or 9 h of incubation (Supplementary Fig. 12). As
controls, free DOX can enter both OVCAR-8 and MCF-7 cells,
concentrate in their nuclei, and induce cytotoxicity. In contrast,
red ﬂuorescence of DOX is observable in all three types of cells
when they are incubated with LSC-D nanoparticles (Supple-
mentary Figs. 12–14). However, DOX is predominantly dis-
tributed in the cytosol and it is barely observable in the nuclei of
NCI/RES-ADR cells even after 9 h of incubation (Supplementary
Fig. 12). On the contrary, in OVCAR-8 and MCF-7 cells, DOX is
observable in their nuclei (Supplementary Figs. 13–14). This
difference is probably a result of the capability of the NCI/RES-
ADR cells to pump out any free DOX slowly released out of the
LSC-D nanoparticles.
Cancer stem-like cells (CSCs) are highly tumorigenic and drug
resistant28–31. The CSCs are likely to be responsible for cancer
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metastasis and tumor recurrence or relapse associated with
conventional therapies32. Therefore, we enriched NCI/RES-ADR,
MCF-7, and OVCAR-8 CSCs in their spheres by using a well-
established method33–36. Free DOX still cannot enter the cells in
the NCI/RES-ADR spheres, whereas LSC-D nanoparticles can
deliver DOX into the cytosol but not the nuclei of the cells, which
is similar to the DOX distribution in 2D NCI/RES-ADR cell
cultures (Supplementary Fig. 15). Although DOX can enter cells
in OVCAR-8 and MCF-7 spheres, the ﬂuorescence intensity is
weaker than that in the corresponding 2D-cultured cells
(Supplementary Figs. 16–17 for spheres, Supplementary Figs. 13–
14 for 2D cell cultures). For OVCAR-8 and MCF-7 spheres
treated with LSC-D nanoparticles, the DOX ﬂuorescence in the
cell nuclei is also weaker than that in the corresponding 2D-
cultured cells. Taken together, these data suggest that using
nanoparticles alone without inhibiting the efﬂux pump activity is
inefﬁcient for overcoming cancer drug resistance.
Production of ROS in mitochondria to combat drug resistance.
ATP is synthesized by using the concentration gradient of
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protons to power the ATP synthase located on the inner mem-
brane of mitochondria (Fig. 3a). To maintain a higher con-
centration of protons outside the inner membrane of
mitochondria, NADH is oxidized into NAD+ to release the
protons out of the inner membrane through an electron transport
chain12. Therefore, we hypothesized that if LSC nanoparticles
could target mitochondria and generate ROS in them, the ROS
could oxidize NADH into NAD+ directly. This should minimize
the concentration gradient of protons across the inner membrane
of mitochondria. As a result, ATP cannot be synthesized by ATP
synthase and the efﬂux pump should become dysfunctional due
to the lack of ATP/energy supply (Fig. 3a).
First, we checked the mitochondria-targeting capability of the
LSC-D nanoparticles. After incubating 2D-cultured NCI/RES-
ADR cells with the nanoparticles for 3 and 9 h, co-localization of
the red ﬂuorescence of DOX with mitochondria (green) is
observable, suggesting that the LSC nanoparticles indeed can
target mitochondria (Supplementary Fig. 18). To further conﬁrm
this, we checked the intracellular distribution of LSC-D
nanoparticles after 9 h of incubation using biological-TEM
(Bio-TEM). As shown in Fig. 3b, most of the mitochondria
contain LSC nanoparticles (arrows). Some of the LSC-D
nanoparticles are in the endosome/lysosome, indicating the cells
take up the nanoparticles via endocytosis (Fig. 3b). Similarly,
some of the red ﬂuorescence of DOX is co-localized with endo/
lysosome (green) and some is co-localized with mitochondria
(purple) when both of them are labeled for confocal imaging
(Supplementary Fig. 19). In contrast, lipid membrane-coated
silica (LS) nanoparticles do not target mitochondria according to
both the confocal and TEM images (Supplementary Figs. 20–21
and Supplementary Note 4). To further conﬁrm the pyruvate-
mediated targeting of mitochondria, we pre-treated/blocked the
NCI/RES-ADR cells with pyruvic acid for 6 h before incubating
them with the LSC nanoparticles. This minimizes mitochondria
binding of the LSC nanoparticles (Supplementary Fig. 21b). More
than 40% of the endosome/lysosome-escaped LSC-D nanoparti-
cles are within mitochondria in the absence of pre-blocking,
whereas it is 0% for the LS-D nanoparticles. With pre-blocking
using pyruvic acid, the percentage decreases from >40% to ~3%
(Supplementary Fig. 21c and Supplementary Note 5). It is worth
noting that free DOX does not change the cellular structure
(Supplementary Fig. 22 and Supplementary Note 6). As the LSC-
D nanoparticles are coated with DPPC on their surface, it is
interesting to understand the fate of the lipid membrane coating
after cellular uptake of the nanoparticles. To this end, ﬂuorescein
isothiocyanate (FITC)-labeled DPPC (FITC-DPPC) is used to
form the membrane coating on the LSC nanoparticles. As shown
in Supplementary Fig. 23, the DPPC membrane can detach from
the nanoparticles after cell uptake although it is stable on
nanoparticles before cell uptake (Supplementary Fig. 24 and
Supplementary Note 7). Taken together, these data support that
the pyruvate group on the surface of the LSC nanoparticles is
responsible for their capability of targeting mitochondria.
We then investigated if LSC nanoparticles can induce the
production of ROS in mitochondria. The production of ROS can
be detected at 3 h after LSC + L, which further increases with time
(Fig. 3c). Importantly, the ROS is well co-localized with
mitochondria (note: the mitochondria tracker can stain the
nuclei only after laser irradiation). Similarly, LSC-D + L-treated
cells also produce strong ROS in their mitochondria. In addition,
the co-localization of DOX and mitochondria conﬁrms the
mitochondria-targeting effect of the LSC-D nanoparticles
(Fig. 3c). More importantly, strong DOX ﬂuorescence can be
clearly observed in the cell nuclei, indicating that the drug
resistance capability of the cells is compromised after the LSC + L
treatment (Fig. 3c). In order to conﬁrm the co-localization of the
ROS and mitochondria throughout the cells, 3D images were
taken and ROS is observable in mitochondria throughout the cells
(Fig. 3c and Supplementary Fig. 25). The quantitative data of ROS
indicate that the NIR laser treatment activates the production of
ROS in LSC nanoparticle-treated cells (Fig. 3d). In contrast, the
ROS production by the free DOX or NIR laser irradiation
treatment alone is minimal (Supplementary Fig. 26).
We further checked the amount of NADH in the cells with the
various treatments. The NADH in cells treated with either LSC
nanoparticles or the NIR laser alone is not signiﬁcantly different
from that of control (medium) group (Fig. 3e). Importantly,
NADH is signiﬁcantly decreased in LSC + L-treated cells. As ROS
can react with NADH but not NAD+, the sum of NADH and
NAD+ is similar for all the groups except the laser-irradiated
group with the highest concentration of LSC (Supplementary
Fig. 27 and Supplementary Note 8). This decrease in NADH but
not the sum of NADH and NAD+ is also observed in LSC + L-
treated OVCAR-8 cells (Supplementary Fig. 28). To further study
the function of mitochondria, a membrane-permeant dye (JC-1)
was used to monitor the mitochondrial membrane potential. As
shown in Supplementary Figs. 29–30, a low mitochondrial
membrane potential can be detected in the LSC + L-treated cells
(Supplementary Note 9). The damage to the membrane of
mitochondria is further conﬁrmed by using Bio-TEM. As shown
in Supplementary Fig. 31, the membrane of mitochondria is not
integral at the locations (arrows) with LSC-D nanoparticles after
laser irradiation. These data indicate mitochondrial damage in
NCI/RES-ADR cells treated with LSC nanoparticles and NIR
irradiation, which is crucial for reducing ATP production and
compromising the function of efﬂux pumps in the cells.
As all the efﬂux pumps are located across the cell plasma
membrane, we isolated the membrane proteins of NCI/RES-ADR
Fig. 3 Overcoming drug resistance by targeted production of reactive oxygen species in mitochondria. a When irradiated with NIR laser, the LSC
nanoparticles can speciﬁcally produce reactive oxygen species (ROS) in mitochondria. This oxidizes NADH into NAD+ to inhibit the production of ATP,
which stops the function of the efﬂux pumps and overcomes the cancer drug resistance. b Representative TEM images of NCI/RES-ADR multidrug-
resistant cells incubated in medium without (Control) or with LSC-D nanoparticles. M indicates the mitochondria. Arrows indicate the LSC-D nanoparticles
in mitochondria. E/L indicates endosome/lysosome. Scale bar: 2 and 0.3 μm for low and high magniﬁcation images, respectively. c Confocal images of
NCI/RES-ADR cells treated with LSC and LSC-D nanoparticles showing the speciﬁc production of ROS in mitochondria. Scale bar: 10 μm. d Quantitative
data on ROS production in NCI/RES-ADR cells under various conditions. Error bars represent s.d. (n= 3). The LSC + L group is compared with the LSC
group with the same LSC concentration, as well as the control (medium) and laser (alone) groups. *p< 0.05 (Kruskal–Wallis H-test). e Relative NADH in
NCI/RES-ADR cells showing the decrease of NADH in cells treated with LSC nanoparticles with laser irradiation (LSC + L, 1W cm−2 for 1 min). Error bars
represent s.d. (n= 3). The LSC + L group is compared with the LSC group with the same LSC concentration, as well as the control (medium) and laser
(alone) groups. *p< 0.05 (Kruskal–Wallis H-test). f Consumption of ATP by the membrane proteins isolated from NCI/RES-ADR cells showing the
transmembrane efﬂux pumps are not bound with ATP in the cells treated with LSC + L so that signiﬁcantly more ATP can be consumed/bound by them.
Error bars represent s.d. (n= 3). The LSC + L group is compared with the LSC group with the same LSC concentration, as well as the control (medium) and
laser (alone) groups. *p< 0.05 (Kruskal–Wallis H-test)
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cells after treatment with LSC nanoparticles. The isolated
membrane proteins were mixed with ATP to determine whether
the efﬂux pumps were active. As shown in Fig. 3f, the membrane
proteins from cells treated with either LSC nanoparticles or NIR
irradiation alone do not consume any ATP. In contrast, ATP is
consumed by the membrane proteins from LSC + L-treated cells.
This indicates the efﬂux pumps in LSC + L-treated cells are not
bound with ATP. If the efﬂux pumps in NCI/RES-ADR cells are
inactive, free DOX should be able to enter the cells and bind with
the cell nuclei. Indeed, DOX is observed in both 2D-cultured
NCI/RES-ADR cells and their spheres after LSC + L treatment
(Supplementary Fig. 32), conﬁrming that efﬂux pumps become
dysfunctional. In order to understand how long the LSC
nanoparticle and laser treatment can inhibit the function of the
efﬂux pumps, we incubated NCI/RES-ADR cells with free DOX
for 3 h at 1–5 days after LSC + L treatment. As shown in
Supplementary Fig. 33, free DOX can enter the cells even after
5 days although the ﬂuorescence intensity of DOX in the cells
gradually decreases with longer waiting time. These data indicate
that the multidrug resistance of NCI/RES-ADR cells can be
successfully overcome by targeted production of ROS in their
mitochondria using a combination of LSC nanoparticles and NIR
laser irradiation. This opens a therapeutic window of at least
5 days for chemotherapy.
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Fig. 4 Overcoming drug resistance by reducing the amount and changing the distribution of P-gp. a Confocal images and ﬂuorescence intensity of P-gp in
NCI/RES-ADR multidrug-resistant cancer cells without any treatment (control) and after treated with LSC nanoparticles with laser irradiation (LSC + L, 1
W cm−2 for 1 min). The data show that the P-gp distributes not only on the cell plasma membrane but also in the cytoplasm after the LSC + L treatment,
whereas it is dominantly located on the plasma membrane for the cells in the control group. In order to conﬁrm the changed distribution of P-gp is owing to
the inhibition of ATP, the multidrug-resistant cancer cells were treated with oligomycin (an inhibitor of ATP synthase) for 12 h at 200 ng ml−1, the results
conﬁrm that inhibition of ATP can inﬂuence the distribution of P-gp. Scale bar: 10 μm. b–c Flow cytometry analysis of P-gp and quantitative data show that
the expression of P-gp is slightly but signiﬁcantly decreased in the multidrug-resistant cancer cells with the LSC + L treatment. These data indicate that
multiple mechanisms contribute to the capability of the LSC + L treatment in overcoming the drug resistance of the multidrug-resistant cancer cells. The
cells were permeabilized for the immunostaining and ﬂow cytometry analyses. Error bars represent s.d. (n= 3). *p< 0.05 (Kruskal–Wallis H-test)
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Distribution and expression of P-gp efﬂux pumps. We next
investigated the amount and distribution of the P-gp efﬂux
pumps in LSC + L-treated NCI/RES-ADR cells. As shown in
Fig. 4a, most of the P-gp efﬂux pumps are located on the cell
plasma membrane for control cells. Interestingly, for LSC + L-
treated cells, many of the P-gp efﬂux pumps are distributed in the
cytoplasm. This might be owing to the minimized ATP produc-
tion so that there is not enough energy supply to transport the P-
gp efﬂux pumps to the cell plasma membrane. To support this, we
incubated the multidrug-resistant cells with oligomycin (an
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Fig. 5 Enhanced anticancer capacity of LSC-D nanoparticles under NIR laser irradiation in vitro. a Owing to the decrease of NADH by ROS oxidization in the
LSC + L-treated group, the cell counting kit-8 (CCK-8) assay that relies on NADH induced color change for quantiﬁcation of cell survival underestimates
the cell survival for the LSC + L-treated cells. b images of live and dead stains showing that most NCI/RES-ADR cells treated with LSC + L are alive, whereas
almost all the cells are dead or detached after treated with LSC-D + L. The nanoparticle concentration was 0.02-1.6 mg ml-1. c–e Viability of NCI/RES-ADR
(c) MCF-7 (d), and OVCAR-8 (e) cancer cells after treated with free DOX, LSC nanoparticles, and DOX-laden LSC (LSC-D) nanoparticles at different
concentrations (0.02–1.6 mgml−1 empty nanoparticle and/or 0.5–40 µg ml−1 DOX) without or with NIR laser (L) irradiation (1W cm−2 for 1 min) quantiﬁed
using crystal violet assay. Error bars represent s.d. (n= 3). f, g Viability of NCI/RES-ADR (f) and OVCAR-8 (g) spheres enriched with CSCs after treated
with free DOX together with LSC or LSC-D nanoparticles at different concentrations (0.5–40 µg ml−1) without or with NIR laser irradiation by using crystal
violet assay. Error bars represent s.d. (n= 3). h Images of live and dead stains showing nearly all cells are alive in spheres with the LSC + L treatment. i–j
Relative NADH in NCI/RES-ADR (i) and OVCAR-8 (j) spheres showing successful inhibition NADH in LSC-treated groups with laser irradiation (LSC + L, 1
W cm−2, 1 min). Error bars represent s.d. (n= 3). The LSC + L group is compared with the LSC group with the same LSC concentration, as well as the
control and laser (alone) groups. *p< 0.05 (Kruskal–Wallis H-test). The ﬁve nanoparticle concentrations (0.02, 0.04, 0.2, 0.4, and 1.6 mgml−1)
correspond to the ﬁve concentrations of DOX (0.5, 1, 5, 10, and 40 µgml−1). Control cells were cultured in medium without any treatment. Scale bars: 100
μm
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-02915-8
8 NATURE COMMUNICATIONS |  (2018) 9:562 |DOI: 10.1038/s41467-018-02915-8 |www.nature.com/naturecommunications
inhibitor of ATP synthase) for 12 h to check the distribution of
the P-gp efﬂux pumps. As shown in Fig. 4a, the P-gp efﬂux
pumps also distributed in both the cell plasma membrane and
cytoplasm, similar to the LSC + L-treated cells. These results
suggest the ATP not only provides the energy for the P-gp efﬂux
pump to function, but also is needed to transport the P-gp efﬂux
pumps to the cell plasma membrane. The total amount of P-gp in
the multidrug-resistant cells from the aforementioned three
groups was studied using ﬂow cytometry. As shown in Fig. 4b, c
and Supplementary Fig. 34, the expression of P-gp is slightly but
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signiﬁcantly decreased compared with control and oligomycin-
treated cells. This together with the increased intracellular dis-
tribution of the P-gp should decrease the amount of the P-gp
efﬂux pumps on the plasma membrane of the LSC + L-treated
cells, which should also reduce the drug-resistant capacity of the
multidrug-resistant cells.
In vitro cytotoxicity. The in vitro anticancer capability of LSC-D
nanoparticles was investigated using NCI/RES-ADR, OVCAR-8,
and MCF-7 cells. As shown in Supplementary Fig. 35a–c, free
DOX is much less toxic to NCI/RES-ADR cells than to OVCAR-8
and MCF-7 cells, conﬁrming the highly drug-resistant nature of
the NCI/RES-ADR cells. Using LSC-D nanoparticles to deliver
DOX can enhance the cytotoxicity of DOX to the multidrug-
resistant cells, but it is still inefﬁcient. When combined with NIR
laser irradiation, the LSC-D nanoparticles can effectively kill all
the three different types of cancer cells. However, laser irradiation
alone does not compromise the viability of any of the three dif-
ferent cells (Supplementary Fig. 36). It is worth noting that the
low cell viability associated with LSC + L treatment is misleading
(Supplementary Fig. 35a–c). This is because the cell viability was
quantiﬁed using the cell counting kit-8 (CCK-8) that uses NADH
to generate color in the sample for quantiﬁcation with colori-
metry. However, the LSC + L treatment can greatly reduce NADH
in cells with minimal change in the color of the CCK-8 solution
(Fig. 5a). This is conﬁrmed by the live (green) and dead (red) cell
staining which shows that most of the LSC + L-treated cells are
alive (Fig. 5b). In contrast, almost all of the LSC-D + L-treated
cells are dead and many of them even detached from the plate at
higher concentrations (Fig. 5b), consistent with the quantitative
CCK-8 data. To further conﬁrm this, crystal violet assay was used
to determine cell viability. As shown in Fig. 5c–e and Supple-
mentary Fig. 37, similar results to that shown in Supplementary
Fig. 35 are obtained except for the LSC + L group.
We further checked the viability of cells in NCI/RES-ADR and
OVCAR-8 spheres enriched with CSCs after various treatments
using crystal violet assay. The NCI/RES-ADR spheres are not
sensitive to free DOX treatment even at the highest concentration
(40 µg ml−1, Fig. 5f and Supplementary Fig. 38a), indicating an
ultra-high drug resistance of the spheres. The OVCAR-8 spheres
also show enhanced resistance to free DOX compared to their
2D-cultured counterparts (Fig. 5g and Supplementary Fig. 38a),
which is in accordance with the uptake data shown in
Supplementary Figs. 13 and 16. Importantly, the LSC-D + L-
treated group exhibited the highest cytotoxicity. Similarly to the
impact on the 2D cell cultures when using CCK-8 assay
(Supplementary Fig. 35), the low cell viability of the LSC + L-
treated spheres quantiﬁed using the CCK-8 assay (Supplementary
Fig. 38b) is owing to the decrease of NADH and the spheres are
highly viable according to live and dead staining (Fig. 5h).
Quantitative data showing the decrease of NADH but not the
sum of NADH and NAD+ in both NCI/RES-ADR and OVCAR-8
spheres after LSC + L treatment are given in Fig. 5i, j and
Supplementary Fig. 39. As discussed above for 2D cell cultures
(Fig. 3c, d), this decrease in NADH is owing to the ROS produced
by LSC nanoparticles in mitochondria after NIR laser irradiation
(Supplementary Fig. 40).
To further conﬁrm the capability of the LSC nanoparticles
under NIR laser irradiation in overcoming multidrug resistance,
two more chemotherapy drugs (paclitaxel or PTX in short and
irinotecan or CPT-11 in short) were separately encapsulated in
the LSC nanoparticles with an encapsulation efﬁciency of 50.1±
0.5 (for PTX) and 52.4± 3.7 (for CPT-11). As shown in Fig. 6a, b,
the PTX or CPT-11 laden LSC nanoparticles (LSC-P or LSC-C)
after irradiated with NIR laser could induce higher cytotoxicity
than the free drugs or drug-laden nanoparticles alone, to both
2D-cultured NCI/RES-ADR cells and 3D-cultured NCI/RES-
ADR spheres. To further conﬁrm that this is due to the
suppression of drug resistance, both 2D-cultured NCI/RES-
ADR cells and 3D-cultured NCI/RES-ADR spheres were
incubated with empty LSC nanoparticles. After irradiated with
NIR laser, the cells were further cultured with free PTX and CPT-
11 for 24 h. As shown in Fig. 6c, the toxicity of free PTX and
CPT-11 to the 2D- and 3D-cultured cells exhibits a dose-
dependent manner and is signiﬁcantly higher than that of the two
free drugs to the cells without the pre-treatment (Supplementary
Fig. 41). This suggests the drug resistance capability of the cells is
suppressed by the LSC + L treatment and free drugs can enter the
cells. Indeed, the cellular uptake data (Fig. 6d, e) show that more
free PTX (labeled with FITC as previously reported37) and CPT-
11 (with blue ﬂuorescence) can enter the 2D- and 3D-cultured
cells (LSC + L, +PF and LSC + L, +C), although the highest drug
ﬂuorescence can be seen in the cells treated with the encapsulated
drugs (i.e., LSC-PF and LSC-C). The latter indicates the
advantage of using nanoparticles for drug delivery. These data
further conﬁrm the drug resistance of the NCI/RES-ADR cells
can be overcome with the treatment of LSC nanoparticles and
NIR laser irradiation, to enhance the antitumor capacity of the
chemotherapy drugs.
In vivo biodistribution and antitumor capability. We next
investigated the biodistribution of LSC and SC nanoparticles in
mice by encapsulating indocyanine green (ICG, an NIR dye) in
the nanoparticles to form LSC-I and SC-I nanoparticles, respec-
tively. As shown in Fig. 7a, at 3 h after intravenous injection, ICG
ﬂuorescence is observable over most of the animal body for all the
formulations. Importantly, enhanced ICG ﬂuorescence in the
tumor area (arrow) is observable only for mice treated with the
Fig. 6 Enhanced anticancer capacity of LSC-P and LSC-C nanoparticles under NIR laser irradiation in vitro. a–b Photographs and quantitative data of crystal
violet assay of 2D-cultured NCI/RES-ADR multidrug-resistant cells a and CSC-enriched NCI/RES-ADR spheres b after treated with free paclitaxel (PTX),
free irinotecan (CPT-11), LSC-C nanoparticles, or LSC-P nanoparticles without or with NIR laser (L) irradiation (LSC-C + L or LSC-P + L, 1W cm−2 for 1 min).
Error bars represent s.d. (n= 3). c Both 2D-cultured NCI/RES-ADR cells and CSC-enriched NCI/RES-ADR spheres were cultured with empty LSC
nanoparticles (0.2 mgml−1) for 12 h. After laser irradiation (1W cm−2 for 1 min), the cells were further cultured with free PTX or CPT-11 dissolved (with the
aid of 1% DMSO) in fresh medium for 24 h, showing the free PTX or CPT−11 could induce more cytotoxicity compared with the free drugs treated cells in
a–b. This is probably owing to the inhibition of drug resistance ability of the cells after the combined treatment of LSC nanoparticles and laser (LSC + L).
Error bars represent s.d. (n= 3). d–e Distribution of PTX-F (PTX labeled with ﬂuorescein isothiocyanate (d) or CPT-11 (e) in free PTX-F or CPT−11, LSC + L
treatment with free CPT-11 or PTX-F (LSC + L, + C or LSC + L, + PF), and LSC-C or LSC-PF treated multidrug-resistant cells. The results of both CPT-11 and
PTX-F show that more drug could be taken up by the multidrug-resistant cancer cells after treated with LSC + L, which further conﬁrms the drug-resistant
capacity of the multidrug-resistant cancer cells can be overcome by treating the cancer cells with LSC nanoparticles and laser. Moreover, the highest drug
ﬂuorescence can be seen in multidrug-resistant cells of the LSC-C and LSC-PF groups, indicating more drugs can be delivered into the multidrug-resistant
cancer cells by encapsulating the drugs in the LSC nanoparticles. The merged views of the ﬂuorescence of CPT-11 and PTX-F with mitochondria further
conﬁrm the capability of the LSC nanoparticles in targeting mitochondria. LSC-P: paclitaxel (PTX) laden LSC nanoparticles and LSC-C: irinotecan (CPT-11)
laden LSC nanoparticles. Scale bars: 20 μm
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Fig. 7 Overcoming cancer drug resistance and augmenting cancer destruction in vivo. a In vivo whole-animal imaging of indocyanine green (ICG)
ﬂuorescence at different times after intravenous injection via the tail vein in the form of free ICG, ICG-laden LSC (LSC-I) nanoparticles, and ICG-laden SC
(SC-I) nanoparticles. The arrows indicate the locations of tumors in mice. b Fluorescence images of DOX in tumors of mice killed at 24 h post injection with
LSC nanoparticles (with and without laser irradiation right before killing the mice). The data suggest the capability of overcoming cancer drug resistance
could be achieved in vivo with the LSC + L treatment. The dashed lines indicate the boundary of the tumor tissue. The boxed regions are shown in higher
magniﬁcation. Scale bar: 200 and 50 μm for low and high magniﬁcation images, respectively. c Growth curves of tumors in mice with various treatments
showing augmented antitumor efﬁcacy of the LSC-D + L treatments. Error bars represent s.d. (n= 7). **p< 0.01, *p< 0.05 (Kruskal–Wallis H-test). d
Representative images of hematoxylin and eosin (H&E)-stained tumor tissue collected after killing the mice on day 64 after the ﬁrst drug administration.
Scale bar: 100 and 50 μm for low and high magniﬁcation images, respectively. e Fluorescence images of DOX in cells isolated form tumors collected on day
64 from mice with different treatments. The cells were incubated with DOX for 3 h. The data show that the drug-resistant capability of the multidrug-
resistant cells in the tumors with the LSC-D + L treatment is still not fully recovered. Scale bar: 80 μm. All non-speciﬁed NIR laser (L) irradiation was at 1W
cm−2 for 2 min. Detached NCI/RES-ADR sphere cells enriched with CSCs were used to obtain xenograft tumors for all in vivo studies
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LSC-I nanoparticles, suggesting the tumor targeting capacity of
LSC nanoparticles. In mice treated with LSC-I nanoparticles, the
ICG ﬂuorescence in the tumor area further increases at 6 h. In
contrast, no ICG ﬂuorescence is observable at 6 h in the tumor
area of mice treated with either free ICG or SC-I nanoparticles.
To conﬁrm the whole-animal imaging data, various organs were
harvested for ex vivo imaging after sacriﬁcing the mice at 6 h.
Indeed, strong ﬂuorescence of ICG can only be detected in the
tumor from LSC-I-treated mouse (Supplementary Fig. 42).
To examine the capability of overcoming cancer drug
resistance of LSC nanoparticles in vivo, mice either with or
without NIR irradiation treatment in the tumor area were
scariﬁed at 24 h after intravenous injection of LSC nanoparticles.
The tumors collected from the killed mice were incubated in
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images of HSF70 showing the HSF70 mainly distributes in cytoplasm. f Confocal images of mutant p53 show the mutant p53 mainly distributes in nuclei.
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medium with DOX for 3 h and then cryo-sectioned for
examination with ﬂuorescence microscopy. As shown in Fig. 7b,
the tumors are still highly drug-resistant because DOX is not
clearly observable in the tumors of mice treated with LSC
nanoparticles alone. More importantly, DOX does enter the cells
in the tumors from mice treated with LSC + L. These observations
indicate that the combination of LSC nanoparticles and NIR
irradiation can overcome cancer drug resistance in vivo.
At last, the safety and antitumor efﬁcacy of the LSC-D
nanoparticles were investigated in vivo. Tumor growth for
treatments with LSC nanoparticles, free DOX, or LSC + L is
similar to that of saline control (Fig. 7c). A decrease in tumor
volume is observable for treatments of LSC-D nanoparticles, and
LSC + L in combination with free DOX (LSC + L + D). The latter
is probably owing to the capability of overcoming cancer drug
resistance by the treatment of LSC + L although free DOX does
not preferentially accumulate in the tumor. Importantly, for LSC-
D + L treatment, complete tumor destruction was observed in two
of seven mice, and both size and weight of the tumors in the LSC-
D + L group were signiﬁcantly less than that of other treatment
groups (Fig. 7c and Supplementary Fig. 43). Moreover,
hematoxylin and eosin (H&E) stain shows extensive necrosis in
the tumors from the LSC-D + L group, whereas tumors from all
the other groups are more viable (Fig. 7d). We further isolated
cells from tumors of all the treatment groups. After growing for
3 days, the cells were incubated with free DOX in medium for 3 h.
As shown in Fig. 7e, cells from tumors treated with saline, LSC,
DOX, LSC-D, and LSC + L are drug resistant. Compared with
tumors treated with LSC + L, more DOX can be seen in cells
isolated from the LSC + L + D-treated tumors, suggesting the
toxicity of DOX to tumor cells can delay the recovery of their
drug resistance. Indeed, DOX ﬂuorescence is strongest in cells
isolated from tumors treated with LSC-D + L because more DOX
can be delivered into tumor with the LSC-D than LSC + L + D
treatment (Fig. 7a).
The body weights of mice were stable during the 64 days of
observation (Supplementary Fig. 44a), probably because we treated
the mice only twice at a low dose of DOX (2.5 mg kg−1 body
weight) and more than 1-month apart. In addition, there is no
obvious damage in the H&E stain of major organs collected from
LSC-D + L-treated mice (Supplementary Fig. 44b). Taken together,
these data suggest the LSC-D nanoparticles are safe for in vivo
treatment.
Discussion
To understand the possible molecular mechanisms of the LSC + L
treatment in sensitizing the drug-resistant cells to cancer therapy,
we investigated the expression of two stress-related proteins in
the NCI/RES-ADR cells ﬁrst. As shown in Fig. 8a, b, the
expression of the 70-kDa heat shock protein (HSP70) is sig-
niﬁcantly decreased at 12 h after the LSC + L treatment compared
with control, NIR laser, or LSC nanoparticles treated cells
although no signiﬁcant change is observable for the expression of
90-kDa heat shock protein (HSP90). HSP70 is abnormally over-
expressed in majority of cancer cells and important for cancer cell
survival38. Therefore, the decrease in HSP70 could make the
cancer cells more sensitive to chemotherapy drugs39. Moreover,
the expression of heat shock factor-1 (HSF-1) that is commonly
thought to be associated with HSP7040, is also decreased at 12 h
after the LSC + L treatment. Previous studies have shown that
high HSF-1 expression is associated with poor outcome of che-
motherapy (including lung, breast, and colon cancer) and
increases CSC frequency41,42. Therefore, the decreased expression
of HSF-1 is beneﬁcial for chemotherapy of not only regular
cancer cells but also the CSCs. It is also worth noting that the
HSP70 and HSF-1 protein complex is required for the stabiliza-
tion of mutant p53 protein in cancer cells43. The decrease of both
HSP70 and HSF-1 should compromise the stability of the mutant
p53 protein. Indeed, the mutant p53 protein is highly expressed
in the NCI/RES-ADR cells and the LSC nanoparticles or NIR
laser irradiation alone has no impact on its expression. Impor-
tantly, it is signiﬁcantly decreased in the LSC + L-treated cells.
Similarly, the mutant p53 is important to the resistance of cancer
cells to both apoptosis and chemotherapy44. We further con-
ﬁrmed the aforementioned observations from western blotting
studies using ﬂow cytometry (Fig. 8c). Confocal ﬂuorescence
images show that the HSF-1 is distributed in both the cytoplasm
and nuclei of cells in the control, NIR laser, or LSC groups, but
decreased in the LSC + L group (Fig. 8d). HSP70 mainly dis-
tributes in the cytoplasm, whereas mutant p53 proteins are
mainly observed in nuclei of cells for the control, laser, or LSC
groups, and both are decreased in LSC + L-treated cells
(Fig. 8e, f). Previous studies show that the expression of P-gp and
mutant p53 shares the same trend in clinical samples45. In
addition, both HSP70 and HSF-1 have been shown to regulate the
expression of P-gp in cancer cells46,47. Therefore, in this study,
the decreased expression of P-gp is possibly owing to the
decreased expression of HSP70, HSF-1, and mutant p53.
In summary, we carefully designed a novel lipid, carbon, and
silica hybrid nanoparticle (Supplementary Note 10), which can be
used to target mitochondria and produce ROS in mitochondria
under NIR irradiation to oxidize NADH for inhibiting the pro-
duction of ATP. This compromises the function of efﬂux pumps
and overcomes the drug resistance of multidrug-resistant NCI/
RES-ADR cancer cells and their CSCs both in vitro and in vivo.
Ultimately, the drug-laden LSC nanoparticles exhibit superior
safety and efﬁcacy for therapy of multidrug-resistant tumors. This
study provides a promising nanotechnology-based strategy for
ﬁghting against cancer multidrug resistance.
Methods
Materials. Cyclohexane, hexanol, triton X-100, toluene, TEOS, APTMS, and ICG
were purchased from Sigma (St. Louis, MO, USA). DPPC and cholesterol were
purchased from Anatrace (Maumee, OH, USA). DOX was purchased from LC
laboratories (Woburn, MA, USA). Irinotecan (CPT-11) was purchased from Sell-
eck Chemicals (Houston, TX, USA). The CCK-8 cell proliferation reagent was
purchased from Dojindo Molecular Technologies (Rockville, MD, USA). Fetal
bovine serum (FBS) and penicillin/streptomycin were purchased from Invitrogen
(Carlsbad, CA, USA). The RPMI 1640 and EMEM cell culture media were pur-
chased from ATCC (Manassas, VA, USA). All other chemicals were purchased
from Sigma unless speciﬁcally mentioned otherwise.
Synthesis of nanoparticles. CCS nanoparticles were prepared as published before48.
In brief, 6 g of glucose was dissolved in 200ml of deionized water, followed by stirring
and sonication to obtain a homogeneous solution. The colorless solution was trans-
ferred into a Teﬂon stainless steel autoclave with 500ml capacity and sealed closely.
Subsequently, the sealed autoclave was heated to 180 °C for 10 h with constant stirring
at ~800 rpm, and then cooled to room temperature passively. Finally, the suspension
containing the as-prepared CCS was transferred into a ﬂask for further character-
ization and use. To prepare SC nanoparticles, distilled water suspended with CCS
nanoparticles was mixed with hexanol (5 ml), triton X-100 (1.7ml), and cyclohexane
(2ml). After added 60 µl of ammonium hydroxide (28 wt%) and 100 µl of TEOS, the
mixture was stirred at 800 rpm using a mini-stir bar for 3, 6, or 12 h at room
temperature. At last, the reaction was stopped by adding 30ml of ethanol. The
nanoparticles were collected by centrifuging at 13,800 g for 10min and washed with
ethanol and water for two times. The APTMS-coated SC nanoparticles were obtained
by incubating the nanoparticles and 20 µl of APTMS in 3ml of ethanol and stirring at
200 rpm using a mini-stir bar at room temperature for 12 h. The preparation and
collection of LSC nanoparticles were conducted as previously reported25. LS nano-
particles were prepared with the same method as that for preparing LSC nanoparticles
except that distilled water was used instead of the CCS nanoparticle suspension
during the preparation of SC nanoparticles.
Characterization of nanoparticles. The size distribution of nanoparticles (1 mg
ml−1 in deionized water) was measured using a Brookhaven 90 Plus/BI-MAS DLS
instrument. FTIR spectroscopy analysis of the nanoparticles was conducted using a
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Perkin Elmer (Waltham, MA, USA) Spectrum 100 FTIR spectrometer according to
the manufacturer’s instruction. In brief, dried samples were grounded in an agate
mortar, mixed with KBr at a ratio of ~1:80 (nanoparticle:KBr) in weight, and
pressed into small discs at 10 tons for 5 min. For proton nuclear magnetic reso-
nance (1H NMR), 2 mg of CCS, SiO2, SC, or LSC nanoparticles were suspended in
1 ml of heavy water (D2O) and characterized using a Bruker 400MHz spectrometer
(Billerica, MA, USA). For TEM characterization, the nanoparticles were imaged
directly or stained with uranyl acetate solution (2%, w/w, for LSC nanoparticles)
using an FEI (Moorestown, NJ, USA) Tecnai G2 Spirit transmission electron
microscope, as detailed elsewhere25. For SEM characterization, 10 µl of nano-
particles in aqueous solutions were dropped on a freshly cleaved mica grid and
dried for 60 min in air. A thin ﬁlm of Au was then sputter-coated onto the
nanoparticles on the substrate. Samples were imaged with an FEI NOVA
Nano400 scanning electron microscope.
Detection of singlet oxygen. Solutions of LSC nanoparticles with or without laser
irradiation were mixed with Singlet Oxygen Sensor Green reagent (Life Technologies,
Carlsbad, CA, USA) and ﬂuorescence (excitation and emission at 488 and 525 nm,
respectively) were measured using a Jasco (Easton, MD, USA) FP-6200
spectroﬂuorometer.
Detection of pyruvate in nanoparticles. The amount of pyruvate in nanoparticles
was measured by the Pyruvate Assay Kit (Sigma). In brief, 50 μg of CCS, SiO2
nanoparticles, SC nanoparticles (reaction times of 3 h and 6 h), or LSC nano-
particles were dissolved in 50 μl of DI water and mixed with Master Reaction Mix
(50 μl containing: Pyruvate Assay Buffer, 46 μl; Pyruvate Probe Solution (colori-
metric), 2 μl; and Pyruvate Enzyme Mix, 2 μl) at room temperature for 30 min in
dark. The amount of pyruvate was then quantiﬁed according to the manufacturer’s
instruction using a Perkin Elmer VICTOR X4 multilabel plate reader.
TEM imaging of cells. Cells were seeded into Nunc Lab-Tek II Chamber Slide
System (Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA) at a density of 1 × 106
cells ml−1 and incubated in medium without (control) or with LSC-D nanoparticles
for 9 h with or without laser irradiation (1W cm−2 for 1 min). Samples were
prepared for TEM according to standard procedures and imaged using an FEI
(Moorestown, NJ, USA) Tecnai G2 Spirit transmission electron microscope.
Detection of reactive oxygen species in cells. NCI/RES-ADR cells were incu-
bated with nanoparticles for 24 h with or without NIR laser irradiation. The cells
were changed with fresh medium containing 25 µM dichloro-dihydro-ﬂuorescein
diacetate (DCFH-DA, Cell Bio Labs Inc., San Diego, CA, USA) and incubated for
45 min. The production of reactive oxygen species (ROS) was measured by
ﬂuorescence intensity using a PerkinElmer (Waltham, MA, USA) VICTORX3
Multilabel microplate reader and studied qualitatively by ﬂuorescence microscopy.
Detection of NADH and NAD+ in cells. NCI/RES-ADR cells (or spheres, ~ 2 ×
105) were incubated with LSC nanoparticles for 12 h. After irradiated with NIR
laser for 1 min, cells were harvested and washed with cold PBS. Cell pellets were
obtained by spinning at 2300 g for 5 min and removing the supernatant. Then, 400
µl of NADH/NAD+ Extraction Buffer (NAD+/NADH Assay Kit (Colorimetric),
Abcam, Cambridge, MA, USA) were added to re-suspend the cells and the
resultant samples were frozen/thawed (20 min on dry ice followed by 10 min at RT)
twice. After mixing for 10 s by vortex, the samples were centrifuged at 4 °C for 5
min. Supernatant (containing extracted NAD+/NADH) was then collected and
transferred into a new tube. For NADH detection, the supernatant was heated at
60 °C for 30 min in water bath to decompose NAD+. A total of 50 µl of the heated
supernatant was mixed with NAD Cycling Buffer (98 µl) and NAD Cycling
Enzyme Mix (2 µl) for 5 min at room temperature. For detection of the sum of
NAD+ and NADH, the supernatant was used directly. A total of 10 µl of NADH
Developer was added and the sample was kept at room temperature for 4 h. The
mixture was then detected quantitatively using a PerkinElmer (Waltham, MA,
USA) VICTORX3 Multilabel microplate reader at 450 nm.
Detection of ATP consumption in cell plasma membrane. Cells were collected by
centrifugation at 600 g for 5min at 4 °C. After washed with 1ml of ice-cold PBS, cells
were re-suspended in 1ml of the Homogenize Buffer Mix (Plasma Membrane Protein
Extraction Kit, Abcam, Cambridge, MA, USA) in an ice-cold Dounce homogenizer
(Corning, Lowell, MA, USA). After transferred the homogenate into a 1.5ml
microcentrifuge tube, the mixture was centrifuged at 700 g for 10min at 4 °C and the
supernatant was further centrifuged at 10,000 g for 30min at 4 °C. The resultant pellet
contains the total membrane proteins. Then, the pellet was mixed with 0.1mM ATP
for 1 h and centrifuged at 10,000 g for 30min at 4 °C to collect the supernatant. The
amount of ATP in the supernatant was measured by an ATP Assay Kit (Abcam,
Cambridge, MA, USA). Brieﬂy, 50 µl of supernatant was mixed with ATP Reaction
Mix (ATP Assay Buffer: 44 µl; ATP Probe: 2 µl; ATP Converter: 2 µl; and Developer
Mix: 2 µl) and incubated at room temperature for 30min in dark. The amount of
ATP in the mixture was then detected quantitatively using a PerkinElmer (Waltham,
MA, USA) VICTORX3 Multilabel microplate reader at 570 nm.
Encapsulation of theranostic agents and drug release. Encapsulation of DOX or
ICG was conducted by mixing it with the nanoparticles at a feeding ratio of 1:20
(DOX or ICG: nanoparticles) in deionized (DI) water for 24 h. To encapsulate
CPT-11, paclitaxel (PTX), or ﬂuorescein isothiocyanate (FITC)-labeled PTX (PTX-
FITC), the (3-Aminopropyl) trimethoxysilane (APTMS)-SC nanoparticles were
mixed with the agent at 1:20 (CPT-11, PTX, or PTX-FITC: nanoparticles) in
ethanol for 24 h. After removing ethanol by evaporation, the nanoparticles were
coated with lipid membrane. The encapsulation efﬁciency (EE) was calculated
using the following equation:
EE ¼ Wencapsulated=W fed ´ 100% ð1Þ
where Wencapsulated represents the amount (in weight) of DOX, CPT-11, PTX, or
ICG encapsulated into nanoparticles and Wfed is the initial total amount of DOX,
CPT-11, PTX, or ICG fed for encapsulation. The amount of DOX, CPT-11, PTX/
PTX-FITC, and ICG was determined spectrophotometrically using a Beckman
Coulter (Indianapolis, IN, USA) DU 800 UV-Vis spectrophotometer based on their
absorbance at 483, 370, 280, and 780 nm, respectively.
To investigate the drug release, drug-laden nanoparticles (20–30 mg) were
dissolved in PBS (5 ml, at pH 7.4) and transferred into a dialysis bag (MWCO: 20
kDa) that was placed in 30 ml of the same PBS solution and stirred at 110 rpm
using a mini-stir bar at 37 °C. For measurement, dialysate was collected and
replenished with same volume of fresh PBS. The released DOX from nanoparticles
was measured using UV-Vis spectrophotometry. For NIR laser irradiation-
triggered drug release, the nanoparticle solution was centrifuged at 13,800 g to
obtain the supernatant. The DOX concentration in the supernatant was analyzed
using UV-Vis spectrophotometry.
Electron paramagnetic resonance spectroscopy. Electron paramagnetic reso-
nance (EPR) measurements were performed on a continuous wave X-band Bruker
EMXPlus EPR spectrometer. Each sample was dissolved in DI water and imme-
diately transferred into a glass capillary tube that was placed in the microwave
cavity of the EPR spectrometer. The applied NIR laser irradiation was at 1W cm−2
for 1 min, where speciﬁed. The concentrations of DEPMPO and LSC nanoparticles
were 20 mM and 2mgml−1, respectively. All EPR spectra were recorded at room
temperature under identical conditions, using 20 mW microwave power, 0.1 G ﬁeld
modulation at 100 kHz, and 16 scans.
Measurement of hydroxyl radical with terephthalic acid. Terephthalic acid (TA)
or 2-hydroxy terephthalic acid (2-HTA) was dissolved in DI water without or with
LSC nanoparticles (2mgml−1). The concentration of TA or 2-HTA was kept at
82.1 nM for all the measurements. After irradiated without or with laser for 1 min
(1W cm−2), the mixture was measured (excitation: 315 nm) using a JASCO FP-6200
spectroﬂuorometer (MD, USA).
Cell culture and in vitro cell viability. Human multidrug-resistant NCI/RES-ADR
cancer cells (human ovarian cancer cell line that was called MCF-7/ADR in early
studies, from ATCC and used without further authentication or test for mycoplasma
contamination) and human breast cancer MCF-7 cells (ATCC) were cultured in
EMEM supplemented with 10% FBS and 1% penicillin/streptomycin at 37 °C
in a humidiﬁed 5% CO2 incubator. Human ovarian cancer OVCAR-8 cells (ATCC)
were cultured similarly in RPMI 1640 medium supplemented with 10% FBS and
1% penicillin/streptomycin. The NCI/RES-ADR cells were used as the drug-
resistant cell model with the MCF-7 and OVCAR-8 cells as the control non-drug-
resistant cell models. For in vitro cell viability studies, OVCAR-8, MCF-7, and
NCI/RES-ADR cells were seeded and incubated with various drug formulations for
12 h. Free DOX and nanoparticles could dissolve in medium directly while free
CPT-11 and PTX were dissolved in dimethyl sulfoxide (DMSO) and then mixed
with medium at the ratio of 1: 100 (DMSO: medium). Then, the medium was
replaced with PBS and if needed, the cells were further treated with near infrared
(NIR) laser irradiation (at 1W cm−2 for 1 min). After treated with laser, cells were
further cultured with various drug formulations for 12 h. The cell viability was then
evaluated using the CCK-8 assay according to the instruction given by the man-
ufacturer (Dojindo Molecular Technologies, Rockville, MD, USA). Cell viability
was calculated as the ratio of the cell number determined for each group to that of
control group with no treatment.
To obtain cancer cell spheres enriched with CSCs, the well-established
suspension culture was used33–35. Brieﬂy, detached single cancer cells were
collected and cultured with CSC medium in 24-well ultralow attachment plates
(Corning, Lowell, MA, USA) at a density of 20,000 cells ml−1. The CSC medium
consisted of DMEM/F12-K supplemented with 5 μg ml−1 insulin, 20 ng ml−1
epidermal growth factor (EGF), 20 ng ml−1 basic ﬁbroblast growth factor (bFGF),
1 × B27 (Invitrogen), and 0.4% (w v−1) bovine serum albumin (BSA). The spheres
were cultured in CSC medium for 10 days and then collected for further
experimental use. To determine cell viability in the spheres, the OVCAR-8 and
NCI/RES-ADR spheres obtained after 10-day suspension culture in the CSC
medium in 24-well plates were further incubated for 12 h in the CSC medium
containing various drug formulations either with or without near infrared (NIR)
laser irradiation (at 1W cm−2 for 1 min). The cell viability was then evaluated with
the CCK-8 assay in the same way as that for the 2D-cultured cells.
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For crystal violet assay, cells were treated in the same way as aforementioned,
and then ﬁxed with 10% methanol and stained with 0.1% crystal violet (dissolved in
10% methanol). After staining, cells were washed three times with PBS and de-
stained with acetic acid. The absorbance of the crystal violet solution was measured
at 590 nm and compared with a standard curve of the known cell numbers versus
the absorbance for interpolation, to determine the cell number in the samples. The
cell numbers under various experimental conditions were normalized to that of the
control condition (in medium all the time) to obtain cell viability.
Flow cytometry analysis. The NCI/RES-ADR cells were incubated in medium
containing various drug formulations for 12 h. After irradiated with laser for 1 min
at 1W cm−2 (if needed), cells were further cultured for 12 h, washed twice with 1 ×
PBS at 37 °C, detached using trypsin/ethylenediaminetetraacetic acid (EDTA), and
ﬁxed with 4% paraformaldehyde for 20 min at room temperature. After washing,
the ﬁxed cells were incubated in 3% BSA and 0.1% TritonX-100 in 1 × PBS at room
temperature for 1 h to block potential nonspeciﬁc binding and permeabilize the cell
plasma membrane, respectively. Following that, the ﬁxed and permeabilized cells
were incubated overnight at 4 °C with HSP90 antibody (Cell Signaling, 4874S),
HSP70 antibody (Cell Signaling, 4872S), mutant p53 antibody (Abcam, ab32049),
HSF-1 antibody (ThermoFisher, PA3–017), and P-gp antibody (Sigma, P7965) at
the dilution ratio of 1:200. Unbounded antibody was washed away with 1 × PBS for
3 times. Cells were then incubated with secondary antibody (ThermoFisher) at the
dilution ratio of 1:200 in 1 × PBS with 1% BSA at room temperature for 1 h. After
washing with 1 × PBS twice, the cells were analyzed using a BD (Franklin Lakes, NJ,
USA) LSR-II ﬂow cytometer and Diva software.
In vitro imaging. Collagen-coated cover glasses (Nunc, Thermo Fisher Scientiﬁc
Inc.) were placed at the bottom in six-well plate. Cancer cells were then collected
and cultured on the cover glasses in the plate at a density of 2 × 105 cells per well at
37 °C for 12 h. The medium was then replaced with 2 ml of fresh medium con-
taining different drug formulations. After incubation at 37 °C for the desired time,
cells were treated with medium containing LysoTracker Green DND-99 (Life
Technologies) and/or MitoTracker Deep Red (Life Technologies) to stain late
endosomes/lysosomes and/or mitochondria, respectively. DOX and CPT-11 have
intrinsic ﬂuorescence and can be imaged directly. For imaging of PTX, it was
labeled with FITC using a previously reported method37. In brief, FITC (5 mg) and
PTX (50 mg) were dissolved in DMSO (2ml) at 90 °C for 2 h in darkness. After
removing DMSO at 90 °C by rotary evaporation for ~12 h, the product was washed
with DI water by centrifugation/precipitation (PTX with and without labeling did
not dissolve in water, whereas FITC did) for three times to remove unreacted FITC.
For P-gp, HSP70, HSF-1, and mutant p53 imaging, cells cultured on collagen-
coated cover glasses were ﬁxed with 4% paraformaldehyde for 20 min at room
temperature. After washing, ﬁxed cells were incubated in 3% BSA and 0.1%
TritonX-100 in 1 × PBS at room temperature for 1 h to block potential nonspeciﬁc
binding and permeabilize the cell plasma membrane, respectively. Following that,
the ﬁxed and permeabilized cells were incubated overnight at 4 °C with the same
antibodies used in the aforementioned ﬂow cytometry studies at the dilution ratio
of 1:200. Unbounded antibody was removed by washing with 1 × PBS for three
times. Cells were then incubated with secondary antibody at the dilution ratio of
1:200 in PBS with 1% BSA at room temperature for 1 h, and washed three times
with 1 × PBS. The cover glass attached with cells was mounted onto a glass slide
with anti-fade mounting medium (Vector Laboratories Burlingame, CA, USA) for
examination using an Olympus FluoView FV1000 confocal microscope.
Western blotting. Cells were cultured and treated similarly to that for the
aforementioned ﬂow cytometry studies. The cells were lysed with RIPA buffer
supplemented with phosphatase inhibitors and protease inhibitors. The proteins
were collected and their concentrations determined with a NanoDrop 2000
Spectrophotometer (Thermo, IL, USA). The protein samples (20 μg) were sepa-
rated on a 10% sodium dodecyl sulphate–polyacrylamide gel and electro-
phoretically transferred to polyvinylidene diﬂuoride membranes in Tris–glycine
transfer buffer. The membranes were blocked in 5% (w v−1) instant nonfat dried
milk for 2 h at room temperature, and incubated with the same primary antibodies
used in the aforementioned ﬂow cytometry studies at the dilution ratio of 1:1000 at
4 °C overnight. The membranes were subsequently washed with Tris Buffered
Saline with Tween 20 (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween
20) and incubated with secondary horseradish peroxidase-conjugated IgG (1:1000)
for 1 h at room temperature. Immunoreactive bands were visualized using che-
miluminescence (ECL Kit; Pierce Biotechnology) and captured by a Bio-Rad
molecular imager. The total intensity of the band for each protein was calculated
with ImageJ and normalized to that of GAPDH. Uncropped images of the western
blot data are shown in Supplementary Fig. 45.
Animals and xenograft tumors. Athymic male NU/NU nude mice (6-week old)
were purchased from Charles River (Wilmington, MA, USA) and maintained on a
16:8 h of light–dark cycle. All procedures for animal use were approved by the
Institutional Animal Care and Use Committee (IACUC) at The Ohio State Uni-
versity. To obtain NCI/RES-ADR xenograft in the nude mice, detached NCI/RES-
ADR sphere cells were suspended in a mixture (1:1) of 1 × PBS and matrigel at 2 ×
105 cells ml−1. A total of 20,000 cells (in 100 μl of the mixture) were subcutaneously
injected at the dorsal side of the upper hind limb of each 7-week-old mouse.
In vivo imaging and biodistribution. When the tumor reached ~5mm in long
diameter, the mice were intravenously injected with 100 µl of saline, 50 µg of free ICG
dissolved in 100 µl of saline, 50 µg of ICG encapsulated in SC nanoparticles dissolved
in 100 µl of saline, or 50 µg of ICG encapsulated in LSC nanoparticles dissolved in
100 µl of saline via the tail vein. All the mice were imaged at 0 (right before injection),
3, and 6 h after injection, using a PerkinElmer (Waltham, MA, USA) IVIS instrument
with excitation at 780 nm and an 831 nm ﬁlter to collect the ﬂuorescence emission of
ICG. For ex vivo imaging, the mice were killed and the major organs (liver, kidney,
lung, spleen, and heart) and tumor were collected for further ex vivo ﬂuorescence
imaging of ICG using the same condition for whole body imaging.
To study the capability of overcoming cancer drug resistance in vivo, mice were
injected with LSC nanoparticles and treated with or without laser irradiation at 12
h after the injection. Then, tumors were collected and cultured in medium with
DOX (10 µg ml−1) for 3 h. After washed with PBS for three times, the tumors were
put in frozen with the Tissue-Tek (Sakura Finetek, Torrance, CA, USA) O.C.T.
Compound and Cryomold at −80 °C for 24 h. The tumors were then cut into slices
of 10 µm thick using a cryo-microtome and transferred onto microscope slides. The
slides were ﬁxed in cold acetone for 10 min and soaked in Tris buffer for 10 min.
The slides were then incubated with 4',6-diamidino-2-phenylindole (1 μg ml−1) and
MitoTracker Deep Red (500 nM) in dark for 10 min to stain the cell nuclei and
mitochondria, respectively. Afterward, the slides were examined using an Olympus
FluoView FV1000 confocal microscope.
In vivo antitumor efﬁcacy and safety. After tumors reached ~5 mm in long
diameter, mice were randomly allocated to each group and treated with 100 μl of
saline, free DOX, LSC nanoparticles without (LSC) or with (LSC + L) NIR laser
irradiation, LSC nanoparticles with NIR laser irradiation and free DOX (LSC + L +
D), LSC-D nanoparticles without (LSC-D) or with (LSC-D + L) NIR laser irra-
diation (n = 7). The number of mice was chosen to guarantee adequate power for
analyzing the difference between the saline and LSC-D + L groups. The blinding
method was not applied for this in vivo animal study. All the drug formulations
were dissolved in 100 μl of saline. The dose of DOX for all the formulations with
the drug was 2.5 mg kg−1 body weight. The NIR laser irradiation was at 1W cm−2
for 2 min and conducted at 12 h after intravenous drug injection. In order to keep
the temperature lower than ~43 °C during laser irradiation, the tumor was passively
cooled at room temperature for 1 min after 1 min of laser irradiation. These
treatments were repeated once on day 34 after the initial treatments. The tumor
volume (V) was calculated as: V = L ×W2 × 0.5, where L is long diameter and W is
short diameter determined using a caliper. The mice were killed on day 64 after the
ﬁrst treatments. Tumors, livers, lungs, hearts, spleens, and kidneys from different
groups were collected and ﬁxed in formalin for H&E staining.
Statistical analysis. All data are reported as mean± standard deviation (s.d.)
from at least three independent runs. The Kruskal–Wallis H-test and the
Mann–Whitney U-test were used to assess the overall among-group and two-group
differences (that follow normal distribution and equal variances), respectively. In
all cases, a p value less than 0.05 was considered to be statistically signiﬁcant.
Data availability. All data supporting the ﬁndings of this study are available from
the corresponding authors upon request.
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